

# ForPatients

by Roche

Type 2 Diabetes Mellitus

## A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes

**Trial Status**

Not Yet Recruiting

**Trial Runs In**

0 Countries

**Trial Identifier**

NCT07351058 2025-523106-32-00  
WC45726

---

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

### *Trial Summary:*

The purpose of this study is to assess the efficacy and safety of RO7795068, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA), at multiple doses compared with placebo for weight management in participants with obesity or overweight and Type 2 diabetes mellitus (T2DM).

**Hoffmann-La Roche**

Sponsor

**Phase 3**

Phase

---

**NCT07351058 2025-523106-32-00 WC45726**

Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**

All

**Age**

>=18 Years

**Healthy Volunteers**

No

---